AU2008349007B2 - Transdermal therapeutic system having urea components - Google Patents
Transdermal therapeutic system having urea components Download PDFInfo
- Publication number
- AU2008349007B2 AU2008349007B2 AU2008349007A AU2008349007A AU2008349007B2 AU 2008349007 B2 AU2008349007 B2 AU 2008349007B2 AU 2008349007 A AU2008349007 A AU 2008349007A AU 2008349007 A AU2008349007 A AU 2008349007A AU 2008349007 B2 AU2008349007 B2 AU 2008349007B2
- Authority
- AU
- Australia
- Prior art keywords
- urea
- ingredient
- skin
- transdermal therapeutic
- layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 239000004202 carbamide Substances 0.000 title claims abstract description 70
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 21
- 239000007787 solid Substances 0.000 claims abstract description 22
- 239000003795 chemical substances by application Substances 0.000 claims abstract 4
- 239000002245 particle Substances 0.000 claims description 30
- 239000004480 active ingredient Substances 0.000 claims description 24
- 239000004615 ingredient Substances 0.000 claims description 20
- 239000011159 matrix material Substances 0.000 claims description 13
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 5
- 229920000058 polyacrylate Polymers 0.000 claims description 5
- 230000003474 anti-emetic effect Effects 0.000 claims description 3
- 229940125683 antiemetic agent Drugs 0.000 claims description 3
- 239000002111 antiemetic agent Substances 0.000 claims description 3
- 229940030600 antihypertensive agent Drugs 0.000 claims description 3
- 239000002220 antihypertensive agent Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 229920000193 polymethacrylate Polymers 0.000 claims description 3
- 239000003368 psychostimulant agent Substances 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 229940035363 muscle relaxants Drugs 0.000 claims description 2
- 239000003158 myorelaxant agent Substances 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 38
- 239000000853 adhesive Substances 0.000 description 9
- 230000001070 adhesive effect Effects 0.000 description 9
- 229920002799 BoPET Polymers 0.000 description 7
- 239000012790 adhesive layer Substances 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 239000011362 coarse particle Substances 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 5
- 239000011241 protective layer Substances 0.000 description 5
- PWWDCRQZITYKDV-UHFFFAOYSA-N 1-benzyl-2-piperazin-1-ylbenzimidazole Chemical compound C1CNCCN1C1=NC2=CC=CC=C2N1CC1=CC=CC=C1 PWWDCRQZITYKDV-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 229950009727 lerisetron Drugs 0.000 description 4
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 4
- 229960000488 tizanidine Drugs 0.000 description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 229960003938 moxonidine Drugs 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- SBTUXKUOKIGYCI-UHFFFAOYSA-N Desgalactotigonin Natural products CC1CCC2(OC1)OC3CC4C5CCC6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(CO)C(OC8OC(CO)C(OC9OCC(O)C(O)C9O)C(O)C8OC%10OC(CO)C(O)C(O)C%10O)C(O)C7O SBTUXKUOKIGYCI-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 229920002633 Kraton (polymer) Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 235000002911 Salvia sclarea Nutrition 0.000 description 1
- 244000182022 Salvia sclarea Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 230000037204 skin physiology Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008006791.1 | 2008-01-30 | ||
| DE102008006791A DE102008006791B4 (de) | 2008-01-30 | 2008-01-30 | Transdermales Therapeutisches System mit Harnstoff-Komponente und Verfahren zu dessen Herstellung |
| PCT/EP2008/010426 WO2009095057A2 (de) | 2008-01-30 | 2008-12-09 | Transdermales therapeutisches system mit harnstoff-komponente |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2008349007A1 AU2008349007A1 (en) | 2009-08-06 |
| AU2008349007B2 true AU2008349007B2 (en) | 2014-10-02 |
Family
ID=40386379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008349007A Expired - Fee Related AU2008349007B2 (en) | 2008-01-30 | 2008-12-09 | Transdermal therapeutic system having urea components |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9066887B2 (enExample) |
| EP (1) | EP2234605B1 (enExample) |
| JP (1) | JP5389824B2 (enExample) |
| KR (1) | KR20100105866A (enExample) |
| CN (1) | CN101909607B (enExample) |
| AU (1) | AU2008349007B2 (enExample) |
| BR (1) | BRPI0821975B8 (enExample) |
| CA (1) | CA2710640C (enExample) |
| DE (1) | DE102008006791B4 (enExample) |
| ES (1) | ES2548295T3 (enExample) |
| MX (1) | MX2010008334A (enExample) |
| PL (1) | PL2234605T3 (enExample) |
| WO (1) | WO2009095057A2 (enExample) |
| ZA (1) | ZA201004012B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106333939A (zh) * | 2016-10-09 | 2017-01-18 | 常州亚环环保科技有限公司 | 一种药用透皮材料的制备方法 |
| CN109549929A (zh) * | 2017-09-27 | 2019-04-02 | 天津金耀集团有限公司 | 一种有机固体溶液降低皮质激素药物粒径的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2867978A1 (fr) * | 2004-03-29 | 2005-09-30 | Galderma Res & Dev | Patch d'amorolfine pour le traitement de l'onychomicose |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1404583A (en) * | 1971-10-08 | 1975-09-03 | Vymatt Sa | Urea compositions and methods of preparation thereof |
| CS164542B1 (enExample) * | 1973-02-15 | 1975-11-07 | ||
| DE2964135D1 (en) * | 1978-06-16 | 1983-01-05 | Phares Pharm Res Nv | Pharmaceutical compositions containing urea |
| US4687481A (en) * | 1984-10-01 | 1987-08-18 | Biotek, Inc. | Transdermal drug delivery system |
| US4699777A (en) * | 1985-08-21 | 1987-10-13 | Schering Corporation | Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea |
| US5230896A (en) * | 1989-10-12 | 1993-07-27 | Warner-Lambert Company | Transdermal nicotine delivery system |
| DE4210165A1 (de) | 1991-07-30 | 1993-02-04 | Schering Ag | Transdermale therapeutische systeme |
| DE4310012A1 (de) * | 1993-03-27 | 1994-09-29 | Roehm Gmbh | Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung |
| WO1997039740A1 (en) | 1996-04-22 | 1997-10-30 | Toyama Chemical Co., Ltd. | Patch containing 1,2-ethanediol derivatives or salts thereof |
| DE19701949A1 (de) * | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
| FR2761889B1 (fr) | 1997-04-11 | 1999-12-31 | Oreal | Patch pharmaceutique, cosmetique ou dermo-pharmaceutique pour la delivrance de plusieurs composes actifs de nature differente |
| US20040018241A1 (en) * | 1997-09-26 | 2004-01-29 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
| GB9826656D0 (en) * | 1998-12-03 | 1999-01-27 | Novartis Ag | Organic compounds |
| JP3962684B2 (ja) * | 2000-11-06 | 2007-08-22 | サムヤン コーポレイション | 改善された水分吸収能および接着性を有する経皮投与剤 |
| IL156353A0 (en) * | 2000-12-15 | 2004-01-04 | Schering Ag | Water-free skin care formulations comprising micronized urea and method of manufacturing the same |
| US20050020658A1 (en) | 2002-11-21 | 2005-01-27 | Katsuyuki Inoo | Selective cyclooxygenase-2 inhibitor patch |
| DE102004028284A1 (de) * | 2004-06-11 | 2006-01-05 | Hexal Ag | Matrixkontrolliertes transdermales therapeutisches System auf Basis eines Schmelzklebstoffs zur Anwendung von Norelgestromin |
-
2008
- 2008-01-30 DE DE102008006791A patent/DE102008006791B4/de active Active
- 2008-12-09 CA CA2710640A patent/CA2710640C/en active Active
- 2008-12-09 JP JP2010544590A patent/JP5389824B2/ja not_active Expired - Fee Related
- 2008-12-09 MX MX2010008334A patent/MX2010008334A/es active IP Right Grant
- 2008-12-09 EP EP08871775.6A patent/EP2234605B1/de active Active
- 2008-12-09 PL PL08871775T patent/PL2234605T3/pl unknown
- 2008-12-09 BR BRPI0821975A patent/BRPI0821975B8/pt not_active IP Right Cessation
- 2008-12-09 CN CN200880124963.5A patent/CN101909607B/zh not_active Expired - Fee Related
- 2008-12-09 AU AU2008349007A patent/AU2008349007B2/en not_active Expired - Fee Related
- 2008-12-09 KR KR1020107017007A patent/KR20100105866A/ko not_active Ceased
- 2008-12-09 ES ES08871775.6T patent/ES2548295T3/es active Active
- 2008-12-09 WO PCT/EP2008/010426 patent/WO2009095057A2/de not_active Ceased
- 2008-12-09 US US12/865,465 patent/US9066887B2/en active Active
-
2010
- 2010-06-04 ZA ZA2010/04012A patent/ZA201004012B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2867978A1 (fr) * | 2004-03-29 | 2005-09-30 | Galderma Res & Dev | Patch d'amorolfine pour le traitement de l'onychomicose |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2234605A2 (de) | 2010-10-06 |
| BRPI0821975B8 (pt) | 2023-02-07 |
| PL2234605T3 (pl) | 2016-01-29 |
| CA2710640A1 (en) | 2009-08-06 |
| ZA201004012B (en) | 2011-02-23 |
| CN101909607A (zh) | 2010-12-08 |
| BRPI0821975B1 (pt) | 2019-10-08 |
| ES2548295T3 (es) | 2015-10-15 |
| CN101909607B (zh) | 2014-05-14 |
| US9066887B2 (en) | 2015-06-30 |
| WO2009095057A3 (de) | 2010-03-04 |
| AU2008349007A1 (en) | 2009-08-06 |
| DE102008006791A1 (de) | 2009-08-06 |
| HK1151716A1 (en) | 2012-02-10 |
| US20100310634A1 (en) | 2010-12-09 |
| MX2010008334A (es) | 2010-08-23 |
| JP2011510936A (ja) | 2011-04-07 |
| KR20100105866A (ko) | 2010-09-30 |
| BRPI0821975A2 (pt) | 2015-06-23 |
| EP2234605B1 (de) | 2015-08-05 |
| DE102008006791B4 (de) | 2011-11-24 |
| WO2009095057A2 (de) | 2009-08-06 |
| CA2710640C (en) | 2015-12-08 |
| JP5389824B2 (ja) | 2014-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101444967B1 (ko) | 활성 물질로서 부프레노르핀을 투여하기 위한 경피 치료 시스템 | |
| AU2010319065B2 (en) | Pharmaceutical composition for external use | |
| JP5881935B2 (ja) | 活性物質の利用率及び用量精度の高い経皮治療システム | |
| CZ287330B6 (en) | Plaster with controlled release of estradiol | |
| HUT77383A (hu) | Szkopolamint tartalmazó tapasz | |
| MXPA04011759A (es) | Emplasto conteniendo fentanilo. | |
| AU2008349007B2 (en) | Transdermal therapeutic system having urea components | |
| RS55034B1 (sr) | Transdermalno sredstvo koje uključuje porozne mikročestice | |
| US20100158990A1 (en) | Transdermal method and patch for corticosteroid administration | |
| KR20090101579A (ko) | 펜타닐을 함유한 경피 흡수제 | |
| KR101353478B1 (ko) | 펜타닐을 함유하는 경피투여용 패취 제제 | |
| HK1151716B (en) | Transdermal therapeutic system having urea components |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |